Food & Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food & Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Internal. Soc. for Pharmacoepidemiology
Risk of heart attack related to COX-2 inhibitors studied
September 24th, 2004
In a poster session containing late-breaking data, researchers at the 20th annual meeting of The International Society for Pharmacoepidemiology Conference on Pharmacoepidemiology in Bordeaux, France, were presented with findings that may have widespread impact for users of anti-inflammatory pain medications. According to principal investigator David J. Graham, of the Office of Drug Safety, U.S. Food and Drug Administration (FDA), "We examined the question of risk of acute myocardial infarction (heart attack) and sudden cardiac death related to the use of the COX-2 inhibitors celecoxib (Celebrex,) and rofecoxib (Vioxx)as well as many traditional NSAIDs, including...
Source: Food & Drug Law Weekly (2004-09-24)
|
